Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Pulmonx Corporation (NASDAQ: LUNG), a leader in minimally invasive lung disease treatments, has announced its participation in the Goldman Sachs 46th Annual Global Health Care Conference. The presentation is scheduled for June 11, 2025, at 7:00 AM PT / 10:00 AM ET in Miami. Investors and interested parties can access both the live and archived webcast of the presentation through the company's investor relations website at investors.pulmonx.com.
Pulmonx Corporation (NASDAQ: LUNG), leader nelle terapie minimamente invasive per le malattie polmonari, ha annunciato la sua partecipazione alla 46ª Conferenza Annuale Globale sulla Sanità di Goldman Sachs. La presentazione è prevista per il 11 giugno 2025, alle 7:00 AM PT / 10:00 AM ET a Miami. Investitori e interessati potranno seguire la diretta e accedere alla registrazione tramite il sito web delle relazioni con gli investitori all'indirizzo investors.pulmonx.com.
Pulmonx Corporation (NASDAQ: LUNG), líder en tratamientos mínimamente invasivos para enfermedades pulmonares, ha anunciado su participación en la 46ª Conferencia Anual Global de Atención Médica de Goldman Sachs. La presentación está programada para el 11 de junio de 2025, a las 7:00 AM PT / 10:00 AM ET en Miami. Inversionistas e interesados podrán acceder a la transmisión en vivo y a la grabación a través del sitio web de relaciones con inversionistas de la compañía en investors.pulmonx.com.
Pulmonx Corporation (NASDAQ: LUNG)는 최소 침습 폐 질환 치료 분야의 선두주자로서 골드만 삭스 제46회 연례 글로벌 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 발표는 2025년 6월 11일 오전 7시 PT / 오전 10시 ET 마이애미에서 예정되어 있습니다. 투자자 및 관심 있는 분들은 회사의 투자자 관계 웹사이트인 investors.pulmonx.com에서 생중계 및 녹화 영상을 시청할 수 있습니다.
Pulmonx Corporation (NASDAQ : LUNG), leader dans les traitements peu invasifs des maladies pulmonaires, a annoncé sa participation à la 46e conférence annuelle mondiale sur la santé de Goldman Sachs. La présentation est prévue le 11 juin 2025 à 7h00 PT / 10h00 ET à Miami. Les investisseurs et parties intéressées pourront accéder à la diffusion en direct ainsi qu'à l'archive via le site des relations investisseurs de la société à l'adresse investors.pulmonx.com.
Pulmonx Corporation (NASDAQ: LUNG), ein führendes Unternehmen im Bereich minimal-invasiver Behandlungen von Lungenerkrankungen, hat seine Teilnahme an der 46. jährlichen Global Health Care Konferenz von Goldman Sachs angekündigt. Die Präsentation findet am 11. Juni 2025 um 7:00 Uhr PT / 10:00 Uhr ET in Miami statt. Investoren und Interessierte können sowohl die Live-Übertragung als auch die Aufzeichnung über die Investor-Relations-Website des Unternehmens unter investors.pulmonx.com verfolgen.
- None.
- None.
REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the company will be presenting at the Goldman Sachs 46th Annual Global Health Care Conference in Miami on Wednesday, June 11, 2025, at 7:00 AM PT / 10:00 AM ET.
A live and archived webcast of the presentation will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.
About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr® Endobronchial Valve, Chartis® Pulmonary Assessment System, LungTrax™ Platform, and StratX® Lung Analysis Reports are designed to assess and treat patients with severe emphysema/COPD who despite medical management are still profoundly symptomatic. Pulmonx received FDA pre-market approval to commercialize the Zephyr Valve following its designation as a “breakthrough device.” The Zephyr Valve is commercially available in more than 25 countries, is included in global treatment guidelines and is widely considered a standard of care treatment option for improving breathing, activity and quality of life in patients with severe emphysema. For more information on the Zephyr Valves and the company, please visit www.Pulmonx.com.
Pulmonx®, AeriSeal®, Chartis®, StratX®, and Zephyr® are registered trademarks and LungTraX™ is a trademark of Pulmonx Corporation.
Investor Contact
Jeremy Feffer
LifeSci Advisors
jfeffer@lifesciadvisors.com
FAQ
When is Pulmonx (LUNG) presenting at the Goldman Sachs Healthcare Conference 2025?
How can I watch Pulmonx's (LUNG) presentation at the Goldman Sachs Conference?
What does Pulmonx Corporation (LUNG) specialize in?
Where is the Goldman Sachs Healthcare Conference 2025 being held?
